C
Cynthia M. Fehres
Researcher at VU University Medical Center
Publications - 19
Citations - 692
Cynthia M. Fehres is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 11, co-authored 14 publications receiving 587 citations. Previous affiliations of Cynthia M. Fehres include Vanderbilt University Medical Center.
Papers
More filters
Journal ArticleDOI
Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells
Wendy W. J. Unger,Astrid J. van Beelen,Sven C. M. Bruijns,Medha D. Joshi,Cynthia M. Fehres,Louis van Bloois,Marleen I. Verstege,Martino Ambrosini,Hakan Kalay,Kamran Nazmi,Jan G. M. Bolscher,Erik Hooijberg,Tanja D. de Gruijl,Gert Storm,Yvette van Kooyk +14 more
TL;DR: The potency of a glycoliposome-based vaccine targeting DC-SIGN for CD4(+) and CD8(+) effector T-cell activation is demonstrated and this approach may offer improved options for treatment of cancer patients and opens the way to in situ DC-targeted vaccination.
Journal ArticleDOI
Understanding the biology of antigen cross-presentation for the design of vaccines against cancer
TL;DR: In this article, the authors summarize new insights in factors that affect antigen cross-presentation of human dendritic cells and discuss the possibilities to exploit antigen crosspresentation for immunotherapy against cancer.
Journal ArticleDOI
Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
TL;DR: The capacity of glycan-based vaccines to enhance antigen-specific CD4(+) and CD8(+) T cell responses in human skin and mouse model systems is discussed.
Journal ArticleDOI
Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens
Cynthia M. Fehres,Hakan Kalay,Sven C. M. Bruijns,Sara A.M. Musaafir,Martino Ambrosini,Louis van Bloois,Sandra J. van Vliet,Gerrit Storm,Juan J. Garcia-Vallejo,Yvette van Kooyk +9 more
TL;DR: It is demonstrated that langerin and DC-SIGN have different size requirements for antigen uptake, although using glycans remains an interesting option in the design of anti-cancer vaccines targeting multiple CLRs, aspects such as molecule size and conformation need be taken in consideration.
Journal ArticleDOI
Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T‐cell cross‐priming
Cynthia M. Fehres,Sven C. M. Bruijns,Astrid J. van Beelen,Hakan Kalay,Martino Ambrosini,Erik Hooijberg,Wendy W. J. Unger,Tanja D. de Gruijl,Yvette van Kooyk +8 more
TL;DR: Topical application of Aldara skin cream significantly enhanced DC migration as compared with that resulting from intradermal injection of the TLR7/8 ligand R848 or the soluble form of imiquimod, and Aldara‐treated DCs showed highest levels of the costimulatory molecules CD86, CD83, CD40, and CD70.